Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China

Table 1 General information obtained from the included studies

Study and publication (yr)	Area of China	Design	Sample	Weight (%)	Regimens		Staging				Operation	Outcome measures		Median follow-up period
							I	II	III	IV		Effectiveness	Economics
Dong[5]	Western-northern	Case-control study	44	5.8	Two cycles at least, and 3-4 wk for one cycle.	FAM	0	7	9	0	UR	(1) CR+PR (WHO tumor response criteria) (2) Median survival time	DMC contained: (1) Drugs (2) Tests (3) Treatment for ADR	UR
						EAP	0	5	6	2
						ELF	0	10	4	1
Yu[6]	Eastern-southern	Case-control study	41	5.4	Four cycles totally, and 28 d for one cycle.	FAM	0	0	5	10	None	(1) CR+PR (WHO tumor response criteria) (2) Median survival time	DMC contained: (1) Drugs (2) Treatment for ADR	UR
						EAP	0	0	3	8
						ELF	0	0	5	9
Ding[7]	Eastern-southern	Case-control study	49	6.4	Two cycles at least, and 3-4 wk for one cycle.	FAM	0	1	8	9	None	(1) CR+PR (WHO tumor response criteria) (2) Median survival time	DMC contained: (1) Drugs (2) Treatment for ADR	UR
						EAP	0	1	5	9
						ELF	0	2	8	6
Qian[8]	Eastern-southern	Case-control study	226	29.7	Two cycles at least, and 3 wk for one cycle.	FAM	Almost composed of stage IV as reported.				Unresectable disease, or palliative operation, or recurrence/metastases after curative operation.	(1) CR+PR (WHO tumor response criteria) (2) Median survival time	DMC contained: (1) Drugs (2) Treatment (3) Fee for berth	UR
						UFTM
						FEP
						LFP/M
Yang[9]	Eastern-northern	Case-control study	256	33.7	Three cycles at least, and 3 wk for one cycle.	FAMTX	All unresectable newly diagnosed patients.				None	(1) CR+PR (2) Median survival time	DMC contained: (1) Drugs (2) Treatment for ADR	26.9 mo
						ECF
Zhou[10]	Eastern-southern	Case-control study	48	6.3	Two cycles at least, and 4 wk for one cycle.	TCF	UR				UR	(1) CR+PR (WHO tumor response criteria) (2) Time-to-progression	DMC contained: (1) Drugs (2) Tests (3) Treatment	UR
						FOLFOX
Liu[11]	Eastern-southern	Case-control study	96	12.6	All six cycles.	DCF	0	0	30	2	UR	CR+PR (Chinese association of gastric cancer response criteria)	DMC contained: (1) Drugs (2) Treatment (3) Fee for berth	UR
						ECF	0	0	29	1
						FOLFOX	0	0	31	3

CR: Complete response; PR: Partial response; DMC: Per capita direct medical cost of single cycle; 5FU: 5-fluorouracil; ADM: Adriamycin; EPI: Epirubicin; MMC: Mitomycin; DDP: Cisplatin; VP-16: Etoposide; CF: Calcium Leucovorin; UFT: Uracil-tegafur; MTX: Methotrexate; PTX: Paclitaxel; DXL: Docetaxel; L-OHP: Oxaliplatin; UR: Unretrieved data; FAM: 5FU+ADM/EPI+MMC; EAP: DDP+VP-16+ADM/EPI; ELF: 5FU+VP-16+CF; UFTM: UFT+MMC; LFP/M: 5FU+CF+DDP+MMC; FAMTX: 5FU+CF+ADM+MTX; ECF: 5FU+EPI+DDP; TCF: 5FU+DDP+PTX; FOLFOX: 5FU+CF+L-OHP; DCF: 5FU+CF+DXL+DDP.